Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called cabozantinib as a possible treatment for
acute myeloid leukemia (AML). This research study is a Phase I clinical trial. Phase I trials
test the safety of an investigational drug or combination of drugs. Phase I studies also try
to define the appropriate dose of the investigational drug to use for further studies. This
means that the FDA has not approved giving cabozantinib for use in patients, including
patients with your type of cancer.
The study drug cabozantinib works by inhibiting several different proteins which are believed
to be involved in the growth and multiplication of the cancerous cells associated with acute
myeloid leukemia. This drug has been used in other research studies and information from
those other research studies suggests that this drug may help to prevent cancer growth.
The primary purpose of this research study is to determine the highest dose of Cabozantinib
that can safely be given without severe or unmanageable side effects. The dose identified in
this study will be used in future research studies that seek to determine the role of
cabozantinib as a treatment for AML.